<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146572">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192399</url>
  </required_header>
  <id_info>
    <org_study_id>C07-001</org_study_id>
    <nct_id>NCT01192399</nct_id>
  </id_info>
  <brief_title>C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients</brief_title>
  <official_title>Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to assess the safety and efficacy of eculizumab in hemolytic
      PNH patients. In addition, the pharmacokinetics (PK) and pharmacodynamic (PD) response of
      eculizumab was assessed and compared to overseas studies of eculizumab treatment in
      hemolytic PNH patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of LDH</measure>
    <time_frame>Baseline to Study Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of total scores of FACIT-Fatigue scale</measure>
    <time_frame>Baseline to Study Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of PNH RBC count</measure>
    <time_frame>Baseline to Study Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of number of units of Packed RBCs transfused</measure>
    <time_frame>Baseline through study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for change of LDH</measure>
    <time_frame>From baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of plasma free hemoglobin</measure>
    <time_frame>From baseline to Study Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of EORTC QLQ-C30 score</measure>
    <time_frame>From baseline to Study Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg of eculizumab as intravenous (IV) infusion once a week for 4 doses, followed by 900 mg eculizumab IV infusion 1 week later for 1 dose, then 900 mg eculizumab IV infusion every 2 weeks for 4 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Subjects were treated with open label Eculizumab and following the dose described in the arm/group description.</description>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese individuals at least 12 years of age

          -  Diagnosis of PNH &gt; 6 months

          -  One transfusion in the past two years for anemia or anemia-related symptoms

          -  LDH level &gt;/= 1.5 x upper limit of normal within 12 weeks

        Exclusion Criteria:

          -  Platelet count &lt; 30,000/microliters

          -  Known or suspected hereditary complement deficiency

          -  History of hematopoietic stem cell transplant

          -  History of meningococcal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Squinto, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alexion Pharmaceuticals</affiliation>
  </overall_official>
  <results_reference>
    <citation>Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011 Jan;93(1):36-46. doi: 10.1007/s12185-010-0748-9. Epub 2011 Jan 12.</citation>
    <PMID>21222185</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>August 30, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemolytic Paroxysmal Nocturnal Hemoglobinuria</keyword>
  <keyword>Eculizumab</keyword>
  <keyword>PNH</keyword>
  <keyword>Japan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
